Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$73.09+3.60(+5.18%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

ARGX · NASDAQ

argenx SE

$873.70 -5.06 (-0.58%)

Company overview

argenx SE, a biotechnology company, engages in developing various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, the Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection; ENHANZE SC; empasiprubart for multifocal motor neuropathy, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$54.9B
Employees
1,599
Headquarters
Amsterdam
Website
argenx.com
CEO
Timothy Van Hauwermeiren
Listed
May 18, 2017
P/E
32.77
Dividend yield
0.00%

Company financials

Revenue
$6.3B
Gross profit
$5.1B
Operating income
$1.2B
EBITDA
$1.3B
Net income
$2.3B
EPS
$26.66
Total assets
$8.7B
Total debt
$83.5M
Gross margin
80.67%
Net margin
36.98%
Earnings yield
3.05%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

742.13827.96913.80999.631,085.47
ARGX 1D NASDAQ O853.28H897.27L853.28C875.76-14.29 (-1.61%)Vol1.02M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ARGX Stock news argenx: 3 Key Takeaways for Long-Term Investors The Motley Fool
ARGX Stock news 714 argenex SE $ARGX Shares Bought by Diversify Advisory Services LLC Defense World
ARGX Stock news argenx SE (ARGX) Q3 2026 Earnings Call Transcript Seeking Alpha
ARGX Stock news What argenex (ARGX) Said on Its Q3 Earnings Call MarketBeat
ARGX Press release argenx Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
ARGX Press release argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 GlobeNewswire
ARGX Press release argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 GlobeNewswire
ARGX Legal ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law Business Wire
ARGX Stock news argenx Meets Primary Endpoint in Phase II Celiac Disease Study Zacks Investment Research
ARGX Stock news argenx shares drop after trial of Vyvgart in Sjögren's disease is halted Proactive Investors
ARGX Stock news Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings Benzinga
ARGX Stock news Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis Benzinga
ARGX Stock news Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Benzinga
ARGX Stock news Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
ARGX Stock news Argenx Shares Plunge After Autoimmune-Disease Trial Halt WSJ
ARGX Press release argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease GlobeNewsWire
ARGX Press release argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease GlobeNewsWire
ARGX Stock news Integrated Wealth Concepts LLC Sells 725 Shares of argenex SE $ARGX Defense World
ARGX Stock news 10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? Fool - Investing News
ARGX Press release argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline GlobeNewswire
See more
FAQ

Questions about argenx SE

What does argenx SE do?
argenx SE, a biotechnology company, engages in developing various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, the Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection; ENHANZE SC; empasiprubart for multifocal motor neuropathy, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
What is ARGX's market cap?
argenx SE (ARGX) is a listed stock with a live quote. The latest market cap on this page is $54.9B.
Where is argenx SE headquartered?
argenx SE is headquartered in Amsterdam.
How do I get ARGX news from the API?
Call GET /v1/news?tickers=ARGX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ARGX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ARGX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ARGX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs